Immunohistochemical Expression Levels of P53 and EIF4E Markers in Histologically Negative Surgical Margins, and Their Association with the Clinical Outcome of Patients with Head and Neck Squamous Cell Carcinoma

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2016 Feb 20

PMID 26893854

Citations 8

Authors

Jagtar Singh

Rama Jayaraj

Siddhartha Baxi

Mariana Mileva

John Skinner

Navneet K Dhand

Mahiban Thomas

Affiliations

Soon will be listed here.

Abstract

Molecular markers can be used to identify residual cancer at the surgical margins of head and neck squamous cell carcinoma (HNSCC) and assist in evaluating the complete resection of the tumour. The purpose of the present study was to investigate the expression levels of prognostic molecular markers at the histological tumour free surgical margins. In the present clinical retrospective study, 24/48 patients were selected with negative surgical margins for further analysis with immunohistochemical staining. Contingency tables and Fisher's exact tests were used to investigate the association between the expression levels of p53 and eukaryotic translation imitation factor 4E (eIF4E) with the clinical outcomes for patients with HNSCC. The expression levels of p53 and eIF4E were 54.2 and 87.5%, respectively, in the surgical margins of patients with HNSCC. A total of 3/7 patients with recurrent cancer (42.8%) were identified with p53-positive margins, and 6 (85.7%) patients exhibited recurrence with eIF4e-positive margins. No statistically significant differences were identified for the recurrence risk between the overexpression of p53 and eIF4E in the surgical margins (P=0.88 and P=0.99, respectively). The eIF4E marker appears to be a more marked prognosticator compared with p53, as overexpression of eIF4E was identified in the margins of 6/7 patients with local recurrence.

Citing Articles

Biological functions and research progress of eIF4E.

Chen X, An Y, Tan M, Xie D, Liu L, Xu B Front Oncol. 2023; 13:1076855.

PMID: 37601696 PMC: 10435865. DOI: 10.3389/fonc.2023.1076855.

Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization.

Pierik A, Leemans C, Brakenhoff R Cancers (Basel). 2021; 13(11).

PMID: 34071997 PMC: 8198309. DOI: 10.3390/cancers13112635.

Molecular margins in head and neck cancer: Current techniques and future directions.

Stepan K, Li M, Kang S, Puram S Oral Oncol. 2020; 110:104893.

PMID: 32702629 PMC: 8131031. DOI: 10.1016/j.oraloncology.2020.104893.

Immunoexpression of p53 in histologically negative surgical margins adjacent to oral squamous cell carcinoma: A preliminary study.

Kamat M, Rai B, Puranik R, Datar U J Oral Maxillofac Pathol. 2020; 24(1):184.

PMID: 32508474 PMC: 7269284. DOI: 10.4103/jomfp.JOMFP_288_19.

Margin Analysis in Head and Neck Cancer: State of the Art and Future Directions.

Li M, Puram S, Silverman D, Old M, Rocco J, Kang S Ann Surg Oncol. 2019; 26(12):4070-4080.

PMID: 31385128 PMC: 7382965. DOI: 10.1245/s10434-019-07645-9.

References

Nathan C, Liu L, Li B, Abreo F, Nandy I, De Benedetti A . Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene. 1997; 15(5):579-84. DOI: 10.1038/sj.onc.1201216. View

van Houten V, Leemans C, Kummer J, Dijkstra J, Kuik D, van den Brekel M . Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res. 2004; 10(11):3614-20. DOI: 10.1158/1078-0432.CCR-03-0631. View

Boyle J, Hakim J, Koch W, van der Riet P, Hruban R, Roa R . The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993; 53(19):4477-80. View

Song H, Do Y, Kang S, Jeong K, Kim Y . Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer. Cancer Res Treat. 2009; 38(4):218-23. PMC: 2741645. DOI: 10.4143/crt.2006.38.4.218. View

Bradford C, Kumar B, Bellile E, Lee J, Taylor J, DSilva N . Biomarkers in advanced larynx cancer. Laryngoscope. 2013; 124(1):179-87. PMC: 4123871. DOI: 10.1002/lary.24245. View

Pihan G, Wallace J, Zhou Y, Doxsey S . Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003; 63(6):1398-404. View

Salehi Z, Mashayekhi F . Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem. 2005; 39(4):404-9. DOI: 10.1016/j.clinbiochem.2005.11.007. View

Crew J, Fuggle S, Bicknell R, Cranston D, De Benedetti A, Harris A . Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer. 2000; 82(1):161-6. PMC: 2363195. DOI: 10.1054/bjoc.1999.0894. View

Breda A, Konijeti R, Lam J . Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev Anticancer Ther. 2007; 7(6):847-62. DOI: 10.1586/14737140.7.6.847. View

10.

Rezende T, Freire M, Franco O . Head and neck cancer: proteomic advances and biomarker achievements. Cancer. 2010; 116(21):4914-25. DOI: 10.1002/cncr.25245. View

11.

Chao Y, Chuang W, Yeh C, Chang Y, Wu Y, Kuo S . High phosphorylated 4E-binding protein 1 expression after chemoradiotherapy is a predictor for locoregional recurrence and worse survival in esophageal squamous cell carcinoma patients. J Surg Oncol. 2011; 105(3):288-92. DOI: 10.1002/jso.22097. View

12.

Nathan C, Sanders K, Abreo F, Nassar R, Glass J . Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications. Cancer Res. 2000; 60(13):3599-604. View

13.

Gasco M, Crook T . The p53 network in head and neck cancer. Oral Oncol. 2003; 39(3):222-31. DOI: 10.1016/s1368-8375(02)00163-x. View

14.

Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X . Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope. 2010; 120(6):1159-65. PMC: 2997737. DOI: 10.1002/lary.20917. View

15.

Waitzberg A, Nonogaki S, Nishimoto I, Kowalski L, Miguel R, Brentani R . Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. Cancer Detect Prev. 2004; 28(3):178-86. DOI: 10.1016/j.cdp.2004.02.003. View

16.

De Benedetti A, Graff J . eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004; 23(18):3189-99. DOI: 10.1038/sj.onc.1207545. View

17.

Cardesa A, Nadal A . Carcinoma of the head and neck in the HPV era. Acta Dermatovenerol Alp Pannonica Adriat. 2011; 20(3):161-73. View

18.

Chakraborty S, Azeem Mohiyuddin S, Gopinath K, Kumar A . Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer. 2008; 8:163. PMC: 2430211. DOI: 10.1186/1471-2407-8-163. View

19.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

20.

Jalali M, Heidarzadeh A, Zavarei M, Sarmast H . p53 overexpression impacts on the prognosis of laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 2011; 12(7):1731-4. View